期刊
ALZHEIMER DISEASE & ASSOCIATED DISORDERS
卷 24, 期 2, 页码 198-203出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/WAD.0b013e3181c53b00
关键词
bapineuzumab; Alzheimer disease; humans; pharmacokinetics; monoclonal antibody
资金
- Wyeth Pharmaceuticals (Collegeville, PA)
- Elan Pharmaceuticals (San Francisco, CA)
The safety, tolerability, and pharmacokinetics (PKs) of bapineuzumab (AAB-001), a humanized monoclonal antibody to amyloid beta, were evaluated in patients with mild-to-moderate Alzheimer disease in a phase 1, randomized, third-party unblinded, placebo-controlled, single ascending dose trial. Thirty patients received bapineuzumab infusion of 0.5, 1.5, or 5mg/kg or placebo (6 active, 2 placebo for 0.5 and 1.5-mg/kg cohorts; 10 active, 4 placebo for 5.0-mg/kg cohort). Three patients in the highest dose cohort (5.0 mg/kg) developed magnetic resonance imaging abnormalities consistent with vasogenic edema, predominantly high signal abnormalities on fluid-attenuated inversion recovery sequences, all of which resolved over time. Plasma amyloid beta was elevated from baseline, peaking approximately 24 hours after infusion. PK analysis demonstrated a half-life of 21 to 26 days, supporting a 13-week dosing interval for bapineuzumab. This small, single-dose study demonstrated the safety pro. le and PK characteristics of bapineuzumab and was used to design later safety and efficacy trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据